|
業務類別
|
Biotechnology |
|
業務概覽
|
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload. |
| 公司地址
| 115 Pullman Crossing Road, Suite 103, Grasonville, MD, USA, 21638 |
| 電話號碼
| +1 410 297-7793 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ostherapies.com |
| 員工數量
| 5 |
| Mr. Gerald E. Commissiong |
Chief Business Officer |
-- |
31/03/2026 |
| Dr. Robert G. Petit, PhD |
Chief Medical Officer and Chief Scientific Officer |
美元 420.00K |
31/03/2026 |
| Mr. Paul A. Romness, M.P.H. |
Chairman of Board, President and Chief Executive Officer |
美元 480.00K |
31/03/2026 |
| Mr. Christopher P. Acevedo |
Chief Financial Officer and Principal Accounting Officer |
美元 36.00K |
31/03/2026 |
|
|
| Mr. Karim Galzahr |
Director |
31/03/2026 |
| Mr. Paul A. Romness, M.P.H. |
Chairman of Board, President and Chief Executive Officer |
31/03/2026 |
| Mr. John Ciccio |
Independent Director |
31/03/2026 |
| Dr. Theodore F. Search, Pharm.D.,R.Ph. |
Independent Director |
31/03/2026 |
| Ms. Avril Suzette McKean-Dieser, J.D. |
Independent Director |
31/03/2026 |
| Mr. Olivier R. Jarry, M.B.A.,M.S. |
Independent Director |
31/03/2026 |
|
|
|
|
